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Background: The Meningococcal Antigen Typing System (MATS) was developed to identify meningococ-
cus group B strains with a high likelihood of being covered by the 4CMenB vaccine, but is limited by the
requirement for viable isolates from culture-confirmed cases. We examined if antigen genotyping could
complement MATS in predicting strain coverage by the 4CMenB vaccine.-binding
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GenotypingMethods: From a panel of 3912 MATS-typed invasive meningococcal disease isolates collected in England
and Wales in 2007–2008, 2014–2015 and 2015–2016, and in 16 other countries in 2000–2015, 3481 iso-
lates were also characterized by antigen genotyping. Individual associations between antigen genotypes
and MATS coverage for each 4CMenB component were used to define a genetic MATS (gMATS). gMATS
estimates were compared with England and Wales human complement serum bactericidal assay
(hSBA) data and vaccine effectiveness (VE) data from England.
Results: Overall, 81% of the strain panel had genetically predictable MATS coverage, with 92% accuracy
and highly concordant results across national panels (Lin’s accuracy coefficient, 0.98; root-mean-
square deviation, 6%). England and Wales strain coverage estimates were 72–73% by genotyping (66–
73% by MATS), underestimating hSBA values after four vaccine doses (88%) and VE after two doses
(83%). The gMATS predicted strain coverage in other countries was 58–88%.
Conclusions: gMATS can replace MATS in predicting 4CMenB strain coverage in four out of five cases, with-
out requiring a cultivable isolate, and is open to further improvement. Bothmethods underestimated VE in
England. Strain coverage predictions in other countriesmatched or exceeded England andWales estimates.
An Audio Summary linked to this article that can be found on Figshare https://figshare.com/articles/
gMATS_video_Vaccine-_2019-_37_7_991-1000_mp4/9326687
 2019 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd. This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction tion level, as for all immunoassays. A genome-based vaccine strainNeisseria meningitidis is the leading cause of bacterial meningitis
and sepsis in children and young adults worldwide [1]. With licen-
sure of 4CMenB (Bexsero, GSK), the first broad coverage meningo-
coccus group B (MenB) vaccine, invasive meningococcal disease
(IMD) has become a vaccine-preventable disease [2,3]. 4CMenB is
a multicomponent vaccine that includes three recombinant protein
antigens, Neisseria adhesin A (NadA), Neisserial Heparin-Binding
Antigen (NHBA), and factor H-binding protein (fHbp), plus
detergent-extracted outer membrane vesicles (OMV) obtained
from the New Zealand outbreak strain, containing porin A protein
(PorA) as main vaccine antigen [4].
Since the incidence of IMD is relatively low, effectiveness of
meningococcal vaccines has been evaluated via an accepted surro-
gate of protection: the serum bactericidal antibody assay with
human complement (hSBA) [5]. Assessing protein-based vaccines
such as 4CMenB is complicated by diversity in the sequence and
expression of MenB surface protein antigens [6]. Predicting efficacy
would require hSBA investigation against a large panel of geneti-
cally diverse and geographically representative pathogenic strains,
which is impractical due to the volumes of serum required [6,7].
The Meningococcal Antigen Typing System (MATS) was devel-
oped to predict strain coverage by 4CMenB from large panels of
meningococcal isolates, independent of human sera [6,8]. MATS
combines genotyping for PorA with three enzyme-linked
immunosorbent assays (ELISA) for fHbp, NHBA, and NadA, that
quantify in meningococcal strains the relative expression and
cross-reactivity of antigenic variants with vaccine-induced anti-
body. Internationally-standardized MATS [9] was shown to provide
a conservative prediction of hSBA results from pooled human sera
[10] and indicated high rates of individual seroprotection [11],
ranging from 66% to 91% in 14 countries [8,12–20].
The UK was the first country to introduce 4CMenB into its
national immunization program (NIP). From September 2015, a
reduced two-dose priming schedule was offered to infants aged 2
and 4 months, with a booster at 12 months, along with limited
catch-up for those born after April 2015 [21]. In the first 10 months
following introduction, two-dose vaccine effectiveness (VE) was
83% (95% confidence interval [95% CI]: 24–95%) against MenB
cases, equivalent to 94% effectiveness against all cases predicted
to be prevented by the vaccine [22].
A limitation of hSBA unresolved by MATS is the inability to use
the assay in non-culture confirmed cases. In some countries,
around half of cases are identified solely by PCR [23,24]. Also,
MATS requires effort in maintaining the international standardiza-coverage predictor would provide a more easily accessible, rapid,
portable, comprehensive, and cost-effective alternative to both
hSBA and MATS assays.
Here, we present 4CMenB vaccine antigen genotyping and
MATS data on over 3000 MenB invasive disease isolates, represent-
ing all notified meningococcal cases in England and Wales in three
epidemiological years together with isolates collected in 16 other
countries. We analyzed the correlation between individual antigen
genotypes and coverage estimates by MATS to define gMATS, a
new genetic Meningococcal Antigen Typing System.
Fig. 1 summarizes the research, clinical relevance and impact on
the patient population.
2. Methods
2.1. Bacterial strains
MATS typing was collected for 3912 invasiveMenB isolates from
13 European and 4 non-European countries (Table 1), recovered
from the blood or cerebrospinal fluid of patients and representative
of national epidemiology in each country at the time of testing. A
subset of 3481 isolates was also typed using antigen genotyping.
2.2. Strain coverage prediction by MATS
Levels of expression and cross-reactivity of fHbp, NadA, and
NHBA were analyzed using the MATS ELISA, according to the
method described previously [6]. Vaccine coverage for these three
components was predicted by defining a relative potency (RP) of
the tested strain versus a reference strain for each antigen and then
comparing the RP with a positive bactericidal threshold (PBT), the
antigen-specific minimum RP value predictive of killing in the
hSBA. If the RP exceeds the PBT for a given antigen, the strain is
predicted as covered by that vaccine antigen. Contribution to cov-
erage by the OMV component was estimated by genotyping, by
sequencing part of the porA gene encoding variable region 2
(VR2) and checking identity to the variant present in the vaccine,
i.e. PorA VR2 match with peptide 4 was defined as ‘covered’ (PorA
VR2 = 4) and other cases as ‘not covered’ [6].
2.3. Strain coverage prediction by genotyping
For the 3481 isolates characterized by genotyping (Table 1),
fHbp and nhba genes were PCR amplified and sequenced, or their
sequences were extracted from the whole genome sequence when
Focus on the Patient
What is the take-home message?
• Our results suggest tha gMATS complement MATS in the estimation of protection provided
by 4CMenB vaccination. 
• This assay may help simplify estimation of vaccine strain coverage and accelerate
surveillance of 4CMEnB vaccine protection. 
What is new?
• We defined a genetic MATS (gMATS) for predicting strain coverage by associating antigen
genotyping and MATS results, using European and non-EU MenB strain panels. 
• In addition to viable isolates, gMATS can be applied to PCR confirmed non-culturable
disease samples. 
• We observed concordant results across national strain panels with gMATS, although both
MATS and gMATS underestimated the effectiveness of the vaccine. 
What is the context?
• 4CMenB is a 4-component, meningococcal group B (MenB) vaccine developed to
protect against related invasive disease. 
• The meningococcal Antigen Typing System (MATS) assay was developed to estimate
the proportion of MenB strains against which 4CMenB vaccinees are protected in a 
given region. 
• The MATS assay requires viable isolates and therefore cannot be applied to non-culture
confirmed cases
Fig. 1. Focus on the Patient section.
Table 1
The global collection of 3912 invasive meningococcal B isolates characterized using the Meningococcal Antigen Typing System (MATS) to
estimate 4CMenB vaccine coverage. A subset of 3481 isolates, collected in ten European countries and three non-European countries, was
also characterized by antigen genotype.
Country (years) Number of
isolates
Predicted 4CMenB strain
coverage by MATS, % (95% CI)
Reference
European countries
Austria (2008–11) 118 68 (56–73) Unpublished
Czech Republic (2007–10) 108 74 (58–87) [12]
Finland (2010–14) 60a 78 (72–88) [20]
France (2007–08) 200a 85 (69–93) [12]
(2013–14) 172a 70 (60–80) Unpublished
Germany (2007–08) 222a 82 (69–92) [12]
Greece (2008–10) 52a 88 (60–96) [13]
Ireland (2009–13) 105a 69 (65–85) Unpublished
Italy (2007–08) 54a 87 (70–93) [12]
Norway (2007–08) 41a 85 (76–98) [12]
Poland (2010–11) 196a 84 (79–91) [14]
Portugal (2011–15) 106 68 (56–81) [15]
Spain (2009–10) 300a 69 (48–85) [17]
UK (2007–08) 535a 73 (57–87) [12]
(2014–15) 251a 66 (52–80) [18]
(2015–16) 174a 73 (56–83) Unpublished
Non-European countries
Australia (2007–11) 520a 75 (61–86) Unpublished
Brazil (2010) 99 81 (71–95) [8]
Canada (2006–09) 157a 66 (46–78) [16]
USA (2000–08) 442a 91 (72–96) [19]
95% CI, 95% confidence interval.
a Isolates also characterized by antigen genotype.
A. Muzzi et al. / Vaccine 37 (2019) 991–1000 993available [25]; the nadA gene was PCR-amplified to determine gene
presence/absence, but was sequenced only in 5% of cases. Alleles
and corresponding peptide identification numbers (IDs; protein
variants) were assigned using the PubMLST Neisseria multilocus
sequence typing database (https://pubmlst.org/neisseria/).Antigen-specific predicted strain coverage by gMATS was
defined by identifying peptide IDs significantly associated with
MATS coverage/non-coverage for that antigen. For fHbp and NHBA
antigens, peptide IDs present in more than five isolates were con-
sidered. Peptide IDs for which the percentage of MATS-covered
994 A. Muzzi et al. / Vaccine 37 (2019) 991–1000strains was higher than 60% or lower than 40% were considered
predictors of coverage or non-coverage, respectively, if a test of
proportions rejected 50% as null hypothesis (p < 0.05 or <0.001).
Peptide IDs not fulfilling these criteria were considered ‘unpre-
dictable’. The same approach was attempted for NadA, testing
the association of nadA gene presence/absence and NadA-MATS
coverage. Coverage for the OMV vaccine component PorA was
genetically defined, as in MATS.
We defined a strain as gMATS ‘covered’ if one or more antigen-
specific gMATS prediction for that strain was ‘covered’. If all
antigen-specific gMATS predictors were ‘not covered’, we defined
the strain as gMATS ‘not covered’. In remaining cases, the strain
was defined as gMATS ‘unpredictable’.2.4. gMATS coverage predictions on national strain panels
Overall, 49% of gMATS ‘unpredictable’ strains were MATS cov-
ered. This observation suggests that empirically we could predict
that half of the ‘unpredictable’ strains could be considered as cov-
ered even by the gMATS method. Therefore, when we applied the
gMATS to estimate the coverage on national strain panels, we used
the proportion of ‘covered’ strains plus half the proportion of ‘un-
predictable’ strains as gMATS final estimation of strain panel cov-
erage. We defined the lower limit of the estimate range as the
proportion ‘covered’, the upper limit as the sum of the proportions
‘covered’ and ‘unpredictable’.Table 2
The genetic Meningococcal Antigen Typing System (gMATS) predictors identified via
analysis of associations between antigen genotype and MATS coverage.
4CMenB
antigen
gMATS predictors
Covered Not covered Unpredictable
fHbp Peptides 1, 2, 4, 14,
15, 37, 89, 90, 110,
144, 224, 232, 245,
249, 252, 510
Peptide 213 and all
variant 2 and 3 peptides
All other fHbp
variant 1
peptides
NHBA Peptides 1, 2, 3, 5, 10,
20, 21, 113, 243
Peptides 6, 13, 17, 18,
19, 24, 25, 30, 31, 43, 47,
58, 112, 114, 120, 122,
160, 187, 253
All other
NHBA
peptides
NadA Never Always Not
applicable
OMV PorA VR2 = 4 PorA VR2– 4 Not
applicable
fHbp, factor H binding protein; NHBA, Neisserial Heparin-Binding Antigen; NadA,
Neisseria adhesin A; OMV, outer membrane vesicles; PorA VR2, porin A variant 2.
Peptide numbers correspond to identification numbers in PubMLST Neisseria
sequence typing database.
Table 3
Single antigen genotyping as predictor of 4CMenB strain coverage estimated using the M
Antigen Typing System (gMATS). The distribution in 2  2 contingency tables of positive/n
non-random (Fisher exact test p-value <1016).
4CMenB antigen
(predictor)
Predicted MATS
outcome
Prediction of MATS MenB strain
Isolates that can be
predicted
Accu
fHbp peptide Coverage by fHbp 84.5 93.6
NHBA peptide Coverage by NHBA 81.5 82.5
nadA gene presence Coverage by NadA 100 98.4
PorA VR2 match Coverage by PorA 100 100
Combined gMATS Coverage by any
antigen
81.3 92.4
Indet., indeterminate.
fHbp, factor H binding protein; NHBA, Neisserial Heparin-Binding Antigen; NadA, Neisse2.5. Comparisons across MenB strain panels
MATS and gMATS predictions for the different strain panels
were compared against each other and against hSBA data from
England and Wales and effectiveness data from England. The hSBA
data were derived from a representative panel of 40 MenB isolates
collected in 2007–2008 using sera from infants after the fourth
4CMenB vaccine dose, as described previously [10]. VE data were
estimated for vaccine-eligible infants with laboratory-confirmed
invasive MenB disease diagnosed in 2015–2016 after two doses
administered as part of the NIP [22].
2.6. Statistical methods
Statistical analyses were performed using the stats and Agree-
ment packages of R 3.3.1 [26,27]. Chi-squared statistical test for
proportions was performed by testing the 50% proportion as null
hypothesis. Fisher exact test for associations, Pearson correlation,
and Poisson regression were performed using default parameters.
Lin’s coefficient of accuracy (Ca) was calculated with
error = ‘‘const”, TDI_a = 5, target = ‘‘random” parameters. MATS
coverage 95% CIs were calculated as described previously [9].
3. Results
3.1. Individual 4CMenB antigen genotypes predict antigen-specific
MATS coverage in 81–84% of strains analyzed
The association between antigen genotype and MATS coverage
was analyzed to identify gMATS predictors. Table 2 reports the
antigen-specific gMATS definitions and Table 3, their statistical
properties as predictors of strain coverage. Since MATS coverage
is already genetically defined for the OMV component, gMATS
and MATS for OMV coincide. The NadA antigen was present in
27% of the strain panel, as demonstrated by nadA gene PCR, but
it is known to be artificially under-expressed under MATS assay
conditions [28]. Consequently, only 1.6% of strains (N = 57) were
NadA-MATS covered. Since the gMATS objective was to reproduce
MATS results, the best predictor of NadA-MATS was the a priori ‘not
covered’ prediction, independent of gene presence/absence or
sequence.
3.1.1. Specific fHbp peptides predict fHbp-MATS coverage for 84% of
strain panel
In the strain panel investigated, 285 different fHbp peptides
were identified, 42 of which were present in more than five iso-
lates (Supplementary Table 1), representing 88% of isolates.
Fig. 2A shows the percentage of strains covered or not covered
by fHbp-MATS for each of the 42 fHbp peptides. Sixteen peptides,eningococcal Antigen Typing System (MATS) and combined genetic Meningococcal
egative antigen genotyping predictions and MATS outcome was always significantly
coverage by genotyping (%)
racy Positive predictive
value
Negative predictive
value
Sensitivity Specificity
90.7 97.9 98.4 87.9
79.9 87.7 92.7 69.1
Indet. 98.4 0 100
100 100 100 100
93.7 85.3 97.1 72.4
ria adhesin A; PorA VR2, porin A variant 2.
Fig. 2. Proportion of the 3481 MenB isolates covered by 4CMenB, as estimated using the Meningococcal Antigen Typing System (MATS), stratified by fHbp (A) or NHBA (B)
antigen genotypes. Genotypes for which MATS coverage can/cannot be predicted are depicted in blue pink respectively. The plots show data for fHbp or NHBA peptides
present in more than five isolates (peptide numbers are identification numbers in PubMLST Neisseria sequence typing database). Footnotes: *p < 0.05; **p < 0.001; §p = 0.07.
fHbp, factor H binding protein; NHBA, Neisserial Heparin-Binding Antigen; gMATS, genetic Meningococcal Antigen Typing System.
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996 A. Muzzi et al. / Vaccine 37 (2019) 991–1000all belonging to fHbp variant 1, showed coverage of at least 79%
and were significantly (p < 0.05) or highly significantly
(p < 0.001) associated with fHbp-MATS coverage. Seventeen pep-
tides belonging to fHbp variants 2 and 3, and variant 1 peptide
ID 213, had coverage of 18% or lower and were significantly asso-
ciated with fHbp-MATS non-coverage (p = 0.07 for ID 23; consid-
ered significant and indicative of non-coverage). Eight peptides,
all belonging to variant 1, were neither positively nor negatively
associated with fHbp-MATS coverage because of small sample size
(frequency 6–8), intermediate coverage or both, and were consid-
ered ‘unpredictable’, along with peptide IDs with population fre-
quency 5. Fourteen frameshifted proteins (0.4% of isolates)
were considered ‘not covered’. With these definitions, 84% of the
strain panel had genetically predictable fHbp-MATS coverage, with
94% predictive accuracy (Table 3).
3.1.2. Specific NHBA peptides predict NHBA-MATS coverage for 81% of
the strain panel
A total of 288 NHBA peptides were identified, 40 of which were
present in more than five isolates (Supplementary Table 2). As
shown in Fig. 2B, nine peptides showed coverage of at least 65%
and were significantly (p < 0.05) or highly significantly
(p < 0.001) associated with NHBA-MATS coverage. Nineteen pep-
tides had coverage of 35% or lower and were associated with
NHBA-MATS non-coverage. Twelve peptide IDs were neither posi-
tively nor negatively associated with NHBA-MATS coverage
because of small sample size (frequency 6–13) or intermediate
coverage. NHBA-gMATS for these and other peptide IDs with pop-
ulation frequency  5 were defined as ‘unpredictable’. Ten frame-
shifted proteins (0.3% of isolates) were considered ‘not covered’.
Overall, 81% of the strain panel had genetically predictable
NHBA-MATS coverage, with 82% predictive accuracy (Table 3).
3.2. gMATS predicts overall MATS strain coverage for 81% of the strains
analyzed
When the four antigen-specific gMATS predictors were com-
bined, 81% of strains in the global panel were predictable by
gMATS (covered or not covered), with 92% prediction accuracy ver-Fig. 3. Regression analysis of predicted coverage of 4CMenB by MATS and gMATS on su
coverage was determined by combining predictions for three vaccine antigens (fHbp,
genetic Meningococcal Antigen Typing System; fHbp, factor H bonding protein; NHBA, Nsus MATS (Table 3). Per national panel, 68–88% of isolates were
gMATS predictable (Supplementary Table 3). Fig. 3 shows the com-
parison of MATS and gMATS predictions for gMATS-predictable
subsets of each panel. The two methods generated highly corre-
lated results (Pearson correlation coefficient 0.88, p < 10 5). The
most discordant panels were from Ireland and Spain (10% over-
and underestimation by gMATS, respectively). Across all countries,
gMATS versus MATS root-mean-square deviation was 5%, indicat-
ing strong concordance. The regression analysis showed gMATS
slightly exceeded MATS for coverage values >80%, although the
95% dispersion area of the regression model always included the
identity, indicating an absence of statistically significant bias.3.3. gMATS reproduces MATS strain coverage predictions on national
panels
Fig. 4 shows the results of the empirical gMATS strain coverage
method applied to the 16 national strain panels, along with corre-
sponding MATS results (see also Supplementary Table 4). gMATS
accurately reproduced MATS point estimates across panels (Lin’s
accuracy coefficient, Ca, 0.98; root-mean-square deviation, 6%),
with similar uncertainty ranges (average width 25% for MATS
and 19% for gMATS) that largely overlapped.3.4. gMATS underestimates England and Wales pooled hSBA results
and VE, and predicts similar or higher strain coverage in other
countries
Within a dataset of 40 isolates representative of meningococcal
disease in England and Wales [10], 100% of gMATS covered strains,
57% of gMATS negative strains, and 75% of gMATS unpredictable
strains were killed in hSBA (Table 4), indicating that gMATS sub-
stantially underestimates killing in hSBA from infant pooled sera.
Fig. 4 also shows that, as with MATS estimates (66–73%), gMATS
(72–73%) underestimated both the hSBA estimate of strain cover-
age in England and Wales (88%, 95% CI: 72–95%) [10] and VE
(83%, 95% CI: 24–95%) in England [22], although with overlapping
ranges.bset of gMATS-predictable strains, in each national strain panel. Predicted gMATS
NHBA and PorA). Foonotes: MATS, Meningococcal Antigen Typing System; gMATS,
eisserial Heparin-Binding Antigen; NadA, Neisseria adhesin A; PorA, Porin A.
Fig. 4. Predicted strain coverage of 4CMenB by MATS and gMATS in England and Wales and 16 other countries. The blue bar represents the England 4CMenB vaccine
effectiveness after two doses, 83% (95% CI, 24–95%) [22]. The green bar represents the hSBA coverage estimate 88% (95% CI, 72–95%) for a panel of 40 isolates tested with
pooled sera from infant and adolescent vaccines and representative of the England and Wales meningococcal epidemiology [10]. The red and white portions of histograms
represent respectively the proportion of gMATS ‘covered’ and ‘unpredictable’ strains for all country-specific panels analyzed. Point estimates of gMATS coverage (‘covered’ +
50% ‘unpredictable’ proportions) are shown as crosses. The proportion of MATS covered strains (point estimates with 95% confidence intervals [CI]) are shown as black circles
for all country-specific strain panels analyzed. The panels of 4 countries (Brazil, Czech Republic, Poland and Austria) were not characterized by genotyping of antigens and
gMATS prediction was not applicable. Foonotes: MATS, Meningococcal Antigen Typing System; gMATS, genetic Meningococcal Antigen Typing System; hSBA, human
complement serum bactericidal assay; VE, vaccine effectiveness.
Table 4
Comparison of bacterial killing in the human complement serum bactericidal assay
(hSBA) with gMATS coverage prediction on 40 representative isolates from England
and Wales [10]. gMATS predicts hSBA with 88% accuracy for 80% of isolates for which
a prediction can be made. Positive and negative predictive values are, respectively,
100% and 43%.
gMATS coverage prediction Infant pooled hSBA result
Killed Not killed
Positive 25 0
Negative 4 3
Unpredictable 6 2
gMATS, genetic Meningococcal Antigen Typing System.
A. Muzzi et al. / Vaccine 37 (2019) 991–1000 997Comparison of gMATS and MATS coverage estimates from Eng-
land and Wales with results from other countries showed percent-
ages ranged from 58% in Spain to 88% in Greece for gMATS, and
from 66% in Canada to 91% in USA for MATS (Fig. 4). 4CMenB strain
coverage in England and Wales, estimated by gMATS or MATS, is
therefore at the lower end of the spectrum of estimates from the
countries investigated so far.4. Discussion
A correlation between MATS and antigen genotype was initially
noted in a previous assessment of predicted strain coverage of
4CMenB [12]. Here, we extended the analysis to a global panel ofover 3900 isolates from MenB disease cases to establish the level
of correlation between MATS and antigen genotyping and define
a new genetic predictor of 4CMenB strain coverage, gMATS.
We found that gMATS could replace MATS in predicting
4CMenB strain coverage in more than 80% of isolates, with 92%
accuracy and 0.98 concordance. The least concordant strain sets
were from Ireland, where gMATS overestimated MATS by 10%
and Spain, where gMATS underestimated MATS by 10%. The reason
of this underestimation in Ireland is mainly related to NHBA MATS
relative potencies close to, but below, the positive bactericidal
threshold for peptides 20 and 21, that are peptides considered
‘covered’ by gMATS. In Spain, the reason is still related to NHBA
MATS relative potencies close to, but above, the positive bacterici-
dal threshold for peptide 17, which is ‘not covered’ by gMATS. Also
worth noting, Spain had the largest proportion of ‘unpredictable’
strains (32%) due to the specific strain epidemiology in this country
[12]. Comparison with hSBA results from England and Wales [10]
and VE data from England [22] confirmed that MATS and gMATS
are conservative predictors of strain coverage. MATS and gMATS
predicted equivalent or higher strain coverage in another 16 coun-
tries, highlighting the potential impact of 4CMenB outside of the
UK.
A major difference between gMATS and MATS is the ‘unpre-
dictable’ strains category in gMATS, allowing for two uses of the
method. When testing a single strain, the gMATS result is either
clear (‘covered’/‘not-covered’) or clearly absent, in which case
998 A. Muzzi et al. / Vaccine 37 (2019) 991–1000another method must be used to determine strain coverage, such
as MATS or hSBA. When estimating strain coverage at a country
level, we considered the proportion of ‘unpredictable’ strains as
the uncertainty of the genetic predictor. Supported by the observa-
tion that, globally, 49% of unpredictable strains by gMATS were
covered by MATS, we defined the gMATS point estimate for
national strain panels as the proportion of gMATS ‘covered’ plus
half the ‘unpredictable’ proportion. This practical, though simplis-
tic, use of gMATS reproduced MATS predictions at a national level
for the 17 countries investigated (accuracy coefficient, Ca, 0.98;
root-mean-square deviation, 6%).
Genotype-phenotype modelling had already shown some pro-
mise in analyses of two subsets of the strain panels investigated
here, as reported by Brehony and Mowlaboccus [29,30] and sum-
marized in Supplementary Table 5. With a larger sample size and
broader geographic representation, overall, gMATS confirms and
significantly extends the associations that were identified
previously.
Compared to immunoassay-based methods, gMATS has the dis-
tinct advantage of not requiring a bacterial isolate and is therefore
not limited to culture-positive cases only. gMATS can be performed
using antigen PCR or methods that allow whole genome sequenc-
ing of N. meningitidis directly from clinical specimens [31]. In the
England study of 4CMenB effectiveness, 70% of MenB cases in
vaccine-eligible infants were confirmed by PCR only [22] indicating
that gMATS, although currently applicable to only 80% of isolates,
has the potential to duplicate MATS’s basis for strain coverage
assessment and accelerate surveillance of 4CMenB VE. Also, gMATS
can substantially simplify laboratory operations as technical
implementation of MATS requires sufficient numbers of samples
to be processed to maintain laboratory proficiency and remain
cost-effective [32].
Current implementation of gMATS has limitations. Like MATS,
gMATS (i) provides a conservative estimate of killing in the hSBA
because it does not consider cooperative effects among antigens
that can mediate killing together but not individually [33,34], (ii)
ignores the effects of minor constituents of OMV [6], and (iii)
underestimates the contribution of NadA antigen to coverage
[28]. gMATS also has specific limitations connected with the
genotype-phenotype association approach: (iv) low-frequency
antigenic variants, including new variants that may appear in the
future, cannot be assessed until enough isolates are collected, v)
future changes in regulatory elements or elsewhere in the genome
– possibly promoted by immune selection and recombination [35]
– may alter the genotype-phenotype association, and (vi) the
threshold-based approach to define ‘covered’/’not covered’ and
the heuristic imputation of ‘unpredictable’ variants, albeit practi-
cal, is ameneable to statistical improvements.
In contrast to immunoassay-based methods, gMATS is open to
potentially unlimited improvement with the accumulation of
prospective genotypic/phenotypic data, including hSBA or VE esti-
mates from countries implementing 4CMenB. Cooperative effects
among antigens could be detected by identifying di-, tri-, or
tetra-antigenic profiles associated with killing in hSBA, or disap-
pearing upon mass vaccination. As previously observed [29], the
frequency of multi-antigen profiles drops dramatically with the
number of antigens included, suggesting that efforts focused on
the most frequent combinations, complementary to single-
antigen predictors, could have higher chances of achieving statisti-
cal significance. Coverage mediated by minor OMV components
could be defined using recently developed, OMV-specific typing
schemes [36]. The NadA contribution could be completely re-
assessed using hSBA or VE estimates for NadA-specific isolates.
Accumulation of phenotypic data on low-frequency variants will
progressively reduce the fraction of ‘unpredictable’ isolates, and
the introduction of typing schemes for regulatory elements[37,38] could clarify the peptide IDs whose phenotype is highly
affected by variability in expression levels. Finally, a probabilistic
error model applied to the joint probabilities of multiple antigens,
both for predictable and unpredictable isolates, would likely fur-
ther improve the accuracy and robustness of the method. As previ-
ously proposed [39], we envision a community effort – possibly
supported by a centralized resource for genotypic and phenotypic
data [40] – whereby accumulation of prospective data from
4CMenB implementation and surveillance programs worldwide
fuels continuous improvements of gMATS, simplifying 4CMenB
strain coverage prediction and accelerating surveillance of 4CMenB
vaccine protection.
In conclusion, gMATS, a new approach based on antigen geno-
typing, can accurately complement MATS in predicting 4CMenB
strain coverage. Both methods underestimated field VE in England,
while strain coverage predictions in 16 other countries matched or
exceeded England and Wales coverage estimates. These results
suggest that gMATS can become a suitable alternative to MATS
for predicting vaccine strain coverage and monitoring vaccine
implementation, and point to a positive potential impact of
4CMenB on IMD globally.
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